Biomarker analysis provides prognostic, predictive, pharmacodynamic (PD), safety, or surrogate endpoint information for therapeutic interventions.
Precise and robust fit-for-purpose biomarker immunoassay methods are needed to support preclinical and clinical biotherapeutic development, with single biomarker assay development typically occurring prior to preclinical studies of a drug candidate. Gyrolab immunoassays provide fully automated, robust assay performance with high precision, a wide dynamic range, and straightforward custom assay development, supporting biomarker analysis in regulated environments.
The recent introduction of the Gyrolab Bioaffy™ 4000 CD expands Gyrolab assay sensitivity for a more powerful solution to biomarker analysis down to low pg/mL levels.
Biomarker quantification using Gyrolab platform positively impacts productivity in the development of therapeutics.
Gyrolab assay protocols are available for the cytokine and other biomarkers below:
Non-human primate
NHP IL-13 | Human/NHP IL-2 |
NHP IL-8 | Human/NHP IL-4 |
Human/NHP IFN-gamma | Human/NHP IL-6 |
Human
Human GLP-1 Active | Human IL-13 | Human TNF-alpha |
Human GLP-1 Total | Human IL-2 | Human VEGF |
Human IFN-gamma | Human IL-22 | Human/NHP IFN-gamma |
Human IL-1 beta | Human IL-4 | Human/NHP IL-2 |
Human IL-10 | Human IL-6 | Human/NHP IL-4 |
Human IL-12p70 | Human IL-8 | Human/NHP IL-6 |
Mouse
Mouse Erythropoietin (EPO) | Mouse IL-17A | Mouse TNF-alpha |
Mouse IFN-gamma | Mouse IL-22 | Mouse IL-17A |
Mouse IL-10 | Mouse IL-4 | Mouse IL-6 |
Mouse TNF-alpha |
Rat
Rat Clusterin | Rat Erythropoietin (EPO) | Rat KIM-1 |
Svar Flexi Solutions (Human Analytes)
Calprotectin | Complement C4d | TCC |